Frederick Beddingfield, Kira CEO

Ki­ra and its com­ple­ment-tar­get in­hibitors plot run to the clin­ic with new in­vestor cash just months af­ter un­cloak­ing

A cou­ple months af­ter emerg­ing from stealth, Ki­ra Phar­ma­ceu­ti­cals has reeled in its largest ven­ture round yet to fund a dash to the clin­ic.

The start­up, co-found­ed back in 2017 by Uni­ver­si­ty of Penn­syl­va­nia pro­fes­sor Wen­chao Song, hooked $53.5 mil­lion in what it calls a “Se­ries B+” fi­nanc­ing. It burst on­to the scene in No­vem­ber, with $18 mil­lion in Se­ries A win­nings and $28 mil­lion from a Se­ries B raised in stealth. With for­mer Si­en­na Bio­phar­ma­ceu­ti­cals CEO Fred­er­ick Bed­ding­field at the helm, the team is on a mis­sion to put three com­ple­ment-tar­get­ed ther­a­pies in the clin­ic over the next 18 months.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.